Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biologic pharmacokinetics and immune effects in adults with chronic rhinosinusitis with nasal polyps
NL-OMON51449Recruiting
- Sponsor
- Erasmus MC
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of dupilumab, omalizumab and mepolizumab in chronic rhinosinusitis with nasal polyps (CRSwNP) (3 cohorts), sponsored by Erasmus MC. Started Jul 2022; status: recruiting.
02
Drugs
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NL-OMON51449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51449.